00:20:42 · John Coogan, Gavin Baker, Jordi Hays
[00:20:42] S0: Yep. [00:20:42] S2: And then the point the point, you know, that Carmen made about, you know, the the forward curve being in contango is actually really important and just like... It's not just that the spot market is tight today. You have to pay vast amount even with all this capacity coming online. You have to pay a truly vast amount to bring on a cluster in mid to late twenty seven. And I think that's something that just maybe public markets are not appreciating even though, you know, it's not all of this is public. You know, Sarah Fryer said that. Yeah. You know, Yeah. Yeah. All these inference clouds have kind of given press releases. You hear a bunch of people on x talk about how hard it is to find compute into '27. [00:21:23] S0: Yep. [00:21:24] S2: Carmen Lee stands up and says, you know, like the market in '27 is is crazy strong. [00:21:30] S0: Yeah. [00:21:30] S2: So it's all out there but I think for whatever reason it's not legible to the public Sure. [00:21:37] S1: Jordan? What... Talk about your outlook on biology as a as a... As an area that that the labs are investing in. It feels very exciting and that there's, you know, tremendous potential, but I think that overall concern is around timelines. It's like there's very real costs, like, coming online, infrastructure costs, and opportunities in biology seem like they're very real, but, may take, you know, years to get these, you know, will almost certainly take years to get drugs in market and actually drive, you know, revenue that would then finance.
00:21:37 · Jordi Hays, Gavin Baker, John Coogan
[00:21:37] S1: Jordan? What... Talk about your outlook on biology as a as a... As an area that that the labs are investing in. It feels very exciting and that there's, you know, tremendous potential, but I think that overall concern is around timelines. It's like there's very real costs, like, coming online, infrastructure costs, and opportunities in biology seem like they're very real, but, may take, you know, years to get these, you know, will almost certainly take years to get drugs in market and actually drive, you know, revenue that would then finance. [00:22:14] S2: Yeah. I mean, we'll we'll see how long it takes. You know, Montana has an interesting new program for for new drugs, I think is helpful. But I think a really big unlock. We we have a lot of compounds and people have used AI to figure out that you can use maybe a drug that we've had for fifty or sixty years for a very rare disease that's devastating for like ten thousand kids a year and effectively cure that disease. And a friend of mine did this and it's, you know, it's it's it's his story to tell, so I'm not gonna tell it. But AI has already saved a lot of lives. And I do think, you know, the AI industry, it's, you know, they're like negative five out of 100 from like a PR. A 100%. [00:23:05] S1: But they... We gotta be more like pharma, [00:23:07] S0: the popular kids. Yeah. Exactly. [00:23:10] S2: Well, no. They need to start telling these stories. [00:23:12] S0: Yeah. Yeah. [00:23:12] S2: Yeah. 100%. And by the way, are... You guys are coming to tomorrow at. [00:23:16] S0: We are.
00:23:16 · John Coogan, Gavin Baker, Jordi Hays
[00:23:16] S0: We are. [00:23:17] S2: Of course. [00:23:17] S0: We are. November seventeenth, eighteenth. We'll be there with [00:23:20] S1: The lineup is unbelievable. [00:23:22] S0: The lineup is crazy. Jensen Huang, David Solomon, Mike Rowan, Lisa Hsu, Stan Druckenmiller, so many more... So many people. Yep. [00:23:30] S2: But the one thing I just wanna say [00:23:32] S0: is Yeah. [00:23:32] S2: I get, like, 25 emails or texts today saying, hey, man. Can I come to your conference? Yeah. And the answer is, you can just sign up. [00:23:42] S0: Yeah. You can just sign up. [00:23:42] S2: Anyone can come. Now, there's gonna be a security screen [00:23:45] S1: Sure. [00:23:46] S2: Because of some of the people who are coming and I do, you know, there are unannounced speakers that are, you know, comparable in caliber to some of those you reference. So we're gonna have a lot of security at the conference and everybody's... You'll be screened. But you can just sign up. You do not need to ask me. You don't need to ask Antonio. You can just come. And it's like the whole goal is to kind of democratize investing. And in in addition to those companies, know, we are... We're gonna have Lynn from Fireworks Yeah. Chase from Crusoe [00:24:16] S0: Yeah. [00:24:17] S2: Scott from Cognition. We're gonna have Max from Lagora. Yeah. We're gonna have a lot [00:24:21] S1: of companies. [00:24:22] S0: Yeah. Base ten.
00:24:22 · John Coogan, Gavin Baker, Jordi Hays
[00:24:22] S0: Yeah. Base ten. [00:24:23] S2: Two in. Two in from Base 10. Yeah. We are gonna have a lot of these CEOs there that are gonna be on a stage and then we're gonna have, you know, dozens of other private CEOs. And, you know, it's a... It's an attempt to kind of, like, open up the aperture of, you know, information for retail investors and democratize this. So, like, if you're wondering about coming, just sign up. You don't need to ask me. [00:24:55] S0: Tomorrow x summit dot com, not Gavin Baker's email. Yes. You can go to a URL on the public. [00:25:03] S1: Can get you can get Gavin to sign And [00:25:07] S0: they will email you when you sign up. Yes. Yeah. Yeah. What what what do you think will change in the content and the conversation between last year's event and this year's event? What are you hoping to get across? [00:25:20] S2: We did... This is the first time... [00:25:22] S0: This is [00:25:22] S2: the first one. Oh, sure. Yeah. Yeah. [00:25:23] S0: Oh, sorry. Yeah.
00:25:23 · John Coogan, Gavin Baker, Jordi Hays
[00:25:23] S0: Oh, sorry. Yeah. [00:25:24] S2: Yeah. We decided we're gonna have, you know, we're gonna have bysiders doing the fireside chats. We're gonna have... You know, management teams are gonna have the opportunity. We've... If you were an active contributor on x, Substack, Reddit Sure. You get to come for free. Yeah. And then management teams are gonna be able to do a breakout session with all of those x accounts. So if you're if you're one of the, you know, four or 500, you know, kind of, you know, financial commentators that we've given a scholarship to, you're gonna get, you know, management teams are gonna opt in and you're gonna be able to kinda have your own session with the management team to ask your questions, then you're gonna be able to go write what you learned for your audience. And I'm... You know, I think we have a really high quality, you know, I mean, I I picked most of them. And you don't have to be bullish. You know, I want... You know, I love skeptics. I love bears. [00:26:23] S0: Yeah. [00:26:23] S2: You just you just have to be polite and nice and constructive. And you can be bearish while being polite, nice and constructive. And, you know, we're... We have loads of we have loads of skeptics. We have loads of optimists. Like, I think it's gonna be great. And then I I hope every CEO does, you know, you know, kind of a hit on your show after they're on stage or before. [00:26:43] S0: Yeah. [00:26:44] S1: I'm... Might TBPN be the episode ever. [00:26:48] S0: I think so.
00:26:48 · John Coogan, Jordi Hays, Gavin Baker
[00:26:48] S0: I think so. [00:26:48] S1: Let's see. Yeah. Do you deal with how how do you deal with all the all the attention? Positive and negative? [00:26:57] S0: That work? [00:26:57] S2: For me? [00:26:58] S1: Yeah. For you. For you. Oh, I know. I just feel like I... You I... You you talked about your your mindset right at the beginning of the show. Just, you know you know, it's a choice to be happy. But I feel like when it comes... When the the the spotlight, you know, once every week shines directly on you. There's a lot of love, a little bit of hate [00:27:19] S2: sprinkled There's... In [00:27:21] S1: The whole the full spectrum of human emotions.